

Oxford Immunotec Global PLC
Form 8-K
March 11, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 8, 2019

OXFORD IMMUNOTEC GLOBAL PLC

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction
of incorporation)

001-36200 98-1133710
(Commission (IRS Employer
File Number) Identification No.)

94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom
(Address of principal executive offices)

Registrant's telephone number including area code +44 (0) 1235 442780

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Dr. Richard Wenstrup, our Chief Medical Officer, resigned from the Company effective March 8, 2019. In connection with his resignation, on March 8, 2019, the Company entered into a separation agreement (the “Separation Agreement”) with Dr. Wenstrup. Pursuant to the terms and conditions of the Separation Agreement, the Company agreed to pay Dr. Wenstrup 10.5 months of severance, payable as salary continuation in accordance with the Company's normal payroll practices. The Separation Agreement contains customary broad form releases and confidentiality provisions. Dr. Wenstrup may revoke the Separation Agreement within a period of seven days following its execution, after which time if not revoked the Separation Agreement will become effective.

The foregoing summary of the Separation Agreement does not purpose to be complete and is subject to and qualified in its entirety by reference to the full and complete terms of the Separation Agreement, a copy of which will be filed as an exhibit to the Company's next periodic report.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 11, 2019

**OXFORD IMMUNOTEC
GLOBAL PLC**

By: */s/ Elizabeth M. Keiley*
Elizabeth M. Keiley

SVP and General Counsel